| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0ed659e76583e448fcf009dcb377e7b3 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16121
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-045
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2800-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16122 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5091
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-701
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56994
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57407 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569 |
| filingDate |
2012-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6513a03c27d95c09f94fde421b35c398 |
| publicationDate |
2017-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9701943-B2 |
| titleOfInvention |
Genetic variant of cytomegalovirus (CMV) |
| abstract |
The present invention relates to a genetic variant of CMV, said genetic variant lacking intron 2 of the IE region of CMV (CMV IEΔi2) The present invention also relates to various uses of this genetic variant as well as RNA splice variants transcribed therefrom, and proteins expressed from the RNA splice variants, such as in the diagnosis of a CMV related cancer disease, and identification of individuals at risk of developing cancer or risk of transferring the CMV IEΔi2 virus with a human sample and prevention and treatment through targeting of unique CMV IE proteins for immunotherapy and vaccination. |
| priorityDate |
2011-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |